吉西他滨联合卡铂治疗转移性乳腺癌的临床观察

Combination of Gemcitabin and Carboplatin in Treatment of Metastatic breast cancer

目的:观察吉西他滨联合卡铂化疗治疗转移性乳腺癌的疗效。方法:针对51例转移性乳腺癌患者,给予吉西他滨联合卡铂治疗,吉西他滨800mg/m2,静脉滴注d1、d8,卡铂AUC 5,静脉滴注d2,21d为1个周期,每例患者治疗2个周期及以上。结果:在51例患者中,经治疗能完全缓解(CR)的12例,能部分缓解(PR)的23例,保持稳定(SD)的9例,发生进展(PD)的7例,有效率达到68.6%,中位疾病进展时间是8.6个月,中位生存时间达到18.3个月。最常见的毒副反应为骨髓抑制,III度以上血小板和白细胞下降发生率分别为23.5%和35.3%,其余毒副反应均轻微,可耐受。结论:采用吉西他滨联合卡铂化疗,能较好地治疗转移性乳腺癌,毒性反应处于可耐受范围。

Objective：To investigated the efficacy and toxicity of the combination of gemcitabin and carboplatin for metastatic breast cancer. Methods：Fifty-one patients with metastatic breast cancer were enrolled into the study. The patients received gemcitabine 800mg/m2 on days l,8 and carboplatin AUC 5 on day 2,with 21 days as a cycle. Each patient received at least two cycles. Results：Of the 51 patients,12 cases got complete response,23 got partial response,9 had stable disease,and 7 had progressive disease,with an overall response rate of 68. 6%. The median time to progression（TTP）was 8.6 months, and median survival time（MST） was 18.3 months. The main toxic reactions were leukopenia（incidence of 35. 3%for grade Ⅲ ＋ Ⅳ）and thrombocytopenia（incidence of 23. 5%for grade Ⅲ ＋Ⅳ）. Conclusion：The combination of gemcitabine and carboplatin is a feasible,well-tolerated and active scheme in treatment of metastatic breast cancer.